The Dales Report
Filament Health Announces Authorization Of Phase 2 Clinical Trial Studying Botanical Psilocybin For Prolonged Grief Disorder
Filament Health Announces Transition From OTCQB To OTC Pink Limited
Filament Health Announces Voluntary Delisting From Cboe Canada
.jpg)
